Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
namodenoson save search
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 4.76%
H: 0.45%
C: -5.91%
drug candidate liver cancer treat namodenoson advanced
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Published: 2024-04-03 (Crawled : 12:00) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 2.45%
H: 0.87%
C: -0.43%
fda namodenoson application trial
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: -0.45%
H: 2.27%
C: 2.27%
europe liver conference distribution pancreatic treatment namodenoson
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
Published: 2023-12-04 (Crawled : 13:30) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 0.0%
H: 1.23%
C: -4.92%
cancer pancreatic treatment namodenoson
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
Published: 2023-09-27 (Crawled : 13:00) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 5.79%
H: 1.82%
C: -8.76%
association cancer pancreatic treatment namodenoson research
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
Published: 2023-07-17 (Crawled : 13:00) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 1.97%
H: 2.43%
C: 0.32%
award liver granted asco cancer treatment namodenoson
Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
Published: 2023-05-30 (Crawled : 12:20) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 7.14%
H: 3.33%
C: 2.71%
pancreatic
Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
Published: 2023-05-15 (Crawled : 12:00) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 0.47%
H: 0.0%
C: -1.4%
europe cancer pancreatic potential
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
Published: 2023-05-02 (Crawled : 12:00) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 13.14%
H: 2.02%
C: 1.01%
cancer pancreatic molecular
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 2.17%
H: 4.25%
C: 0.0%
pharma conference piclidenoson companies namodenoson spring
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
Published: 2023-03-13 (Crawled : 12:00) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 10.08%
H: 0.0%
C: -7.69%
namodenoson cirrhosis liver
Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
Published: 2023-01-24 (Crawled : 13:00) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 1.98%
H: 3.87%
C: -8.14%
namodenoson patent preclinical cancer pancreatic
Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®
Published: 2022-10-25 (Crawled : 12:00) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 11.49%
H: 2.25%
C: -1.32%
meeting clearance namodenoson liver cancer
Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference
Published: 2022-10-13 (Crawled : 12:00) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: -2.76%
H: 4.08%
C: 4.08%
namodenoson drug candidate conference nash
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania
Published: 2022-08-23 (Crawled : 12:00) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 3.37%
H: 6.52%
C: 3.65%
treatment drug liver approved cancer a3ar namodenoson
Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
Published: 2022-06-09 (Crawled : 12:00) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: -2.94%
H: 5.14%
C: 2.61%
publication piclidenoson namodenoson
Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
Published: 2022-05-02 (Crawled : 12:00) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 9.47%
H: 0.0%
C: -6.39%
ceo liver immunotherapy cancer namodenoson
Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office
Published: 2022-03-14 (Crawled : 12:30) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 6.19%
H: 4.85%
C: -8.49%
treatment fibrosis patent liver namodenoson
Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson
Published: 2022-01-31 (Crawled : 15:00) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: -1.74%
H: 3.54%
C: 3.54%
trial nash enroll namodenoson
Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
Published: 2021-12-20 (Crawled : 12:30) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 88.98%
H: 8.33%
C: -10.42%
liver cancer namodenoson
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.